知镜 Cognispect · 医学文献与研究工作台

Real-world systemic treatment outcomes for moderate-to-severe atopic dermatitis in children by skin color: 4-year results from the observational, international, real-world PEDISTAD registry.

Paller AS, Eichenfield LF, Wine Lee L, Ramien M, Ma L, López Carrera YI, Joyce JC, Gonzalez ME, Capozza K, Hamad S, Ardeleanu M, Zhang A.
Journal of the American Academy of Dermatology · 2026-09-21 · PMID 42767466

文献摘要

Background Atopic dermatitis (AD) can have different genetic, immunopathogenic, and clinical features depending on the ethnicity of the affected individual. Objective To investigate if White and non-White children with moderate-to-severe AD respond differently to systemic treatment. Methods PEDISTAD is an observational, international, real-world study. Patients were analyzed in 2 subgroups: non-White and White. Non-White included Black/African American, Asian, American Indian or Alaskan-Native and Multiracial. Results 314 White, and 186 non-White children Conclusion In this study, patients that received dupilumab had a greater observed improvement in clinician- and patient-reported outcomes compared with patients receiving methotrexate and cyclosporine irrespective of skin color/race.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。